Hartmut M. Goldschmidt

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 473 publications

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Journal: Nature medicine

Published: July 06, 2026

Erratum to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial".

Erratum to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial".

Journal: Haematologica

Published: July 01, 2026

Publisher Correction: Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.

Publisher Correction: Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.

Journal: NPJ digital medicine

Published: June 16, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2026

Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 20, 2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Journal: Leukemia

Published: February 18, 2026

Erratum to: Detection of myeloma-associated osteolytic bone lesions with energy-integrating and photon-counting detector CT.

Erratum to: Detection of myeloma-associated osteolytic bone lesions with energy-integrating and photon-counting detector CT.

Journal: Radiologie (Heidelberg, Germany)

Published: January 13, 2026

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.

Journal: International journal of cancer

Published: October 31, 2025

Showing 1-12 of 473

Last Updated: 09/26/2026